ACHN


We Remain Positive And Consistent With Our Bullish Investment Thesis On Achillion, Says Maxim

In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, …

Maxim Remains Bullish On Achillion Pharmaceuticals, Sees 59% Upside

In a research report released Monday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price …

Achillion Pharmaceuticals: Still Bullish, But Taking Profits

Entry: $9.86 10/2/14 Take Profits: $14.

Maxim Maintains Buy On Achillion Pharmaceuticals Following 3Q14 Update

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price …

Achillion: Positioned To Deliver The Last Clinical Stage Nuc To The Highest Bidder

Investment Thesis We expect volatility in the share prices of HCV focused companies leading into this year’s AASLD meeting from November 7th to …

Maxim Reiterates Buy Rating And Raises Achillion Price Target To $22

In a research note issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating and boosted his price target on Achillion Pharmaceuticals (ACHN) to …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts